Company Overview of Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for prostate cancer and other hormonally-driven diseases. Its lead drug candidate is galeterone, an oral small molecule that is in various clinical trials for the treatment of patients with metastatic castration-resistant prostate cancer. The company’s androgen receptor degradation (ARDA) drug discovery program is focused on identifying and developing compounds for ARDA activity. Tokai Pharmaceuticals, Inc. was founded in 2004 and is based in Boston, Massachusetts.
255 State Street
Boston, MA 02109
Founded in 2004
Key Executives for Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Key Developments
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3D Bio Holdings LLC||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|Bloomberg L.P.||United States|
|The Advertising Council, Inc.||United States|
|Rush University||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Tokai Pharmaceuticals, Inc., please visit www.tokaipharmaceuticals.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.